Amboy Street Ventures invests $1m in Contraline

Amboy Street Ventures (ASV) is excited to announce its latest $1m investment in Contraline, to enable the brand to conduct what is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years with its innovation ADAM™. The trial will launch the next generation of non-hormonal male contraceptives, increasing choice for men and achieving public health impact.

ASV Insights – Top 10 Deals of 2021: Queen V and the trend of CPG conglomerates seeking innovation through acquisition

This week we look at companies in women’s health and sexual health that have been acquired by CPG conglomerates.

ASV Insights – Top 10 Deals of 2021: Sexual health and women’s health medical device M&A activity is on the rise

This week we look at the rise of M&A activity around women’s health and sexual health medical device innovations.

ASV Insights – Top 10 Deals of 2021: The surge of telehealth and subscriptions for birth control

This week we look at the growing demand for at-home birth control subscriptions.

ASV Insights – Top 10 Deals of 2021: How Flo’s $50m Series B financing signals the boom in the menstrual market

This week we look at the incredible rise of successful companies in the menstrual market.

ASV Insights – Top 10 Deals of 2021: The rise of connected health devices

This week we discuss how connected breast pump and smart pelvic floor exerciser, Elvie, is one of the latest rising successes in connected health devices.

ASV Insights – Top 10 Deals of 2021: The Rise of the Hybrid Healthcare Delivery Model

This week we consider the rise of a hybrid model of healthcare that combines bricks and mortar with Telehealth services.

ASV Insights – Top 10 Deals of 2021: Kindbody, the fertility trailblazer

This week we look at the fertility landscape following the success of Kindbody.

Fast track our industry.
Get in touch today.